Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65~* For patients younger than 50 years, cons-indication for the use of a standard myeloablative conditioning (history of hematopoietic stem cell transplantation autologous or allogeneic, or the presence of co-morbidities or medical history making prohibitive in terms toxicity using chemotherapy and / or high dose radiotherapy as judged by the referring physician) - MDS, ALL or AML at high risk, WHO THE biphenotypic-Score \<2~* Any primary diagnosis of high-risk MDS/AML or ALL eligible for a treatment by reduced intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-SCT)~* Suitable donor available (related or matched unrelated)~* Cardiac: LV Ejection Fraction ≥ 50% by MUGA or Echocardiogram.~* Pulmonary: FEV1 and FVC ≥ 50% predicted, and DLCO (corrected for hemoglobin) ≥ 50% of predicted~* Adequate renal and hepatic function~* Performance status: Karnofsky ≥ 70%~* Informed consent signed by patient prior to enrolment~Exclusion Criteria:~* Age \<18~* Age \>65~* Known hypersensitivity to clofarabine or excipients- Other hematologic malignancies than ALL, AML and MDS~* Patients with prior standard allogeneic HSCT with grade \> 2 aGvHD~* Prior standard allogeneic transplantation if \< 2 months~* Contra-indication to one of the drug of the RIC regimen .~* Patient with \> 3 treatment lines prior to inclusion~* Pregnant or lactating females~* Patient HIV+, Hep B+, Hep C+- Uncontrolled systemic infection~* Performance Status Score ECOG \> 2- Known central nervous system involvement with AML or ALL- Uncontrolled active infection of any kind or bleeding~* Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo the agents included in the conditioning regimen.~* For patients younger than 50 years, possibly indicating a standard myeloablative conditioning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).